Abbott India

Pick of the Week: Abbott India Ltd

Equity Bottom-Up
129 Views, 11 Jan 2022 17:07
EXECUTIVE SUMMARY
  • Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of new products
  • AIL has leadership position in 9 top brands out of 10 in their respective therapies
  • We recommend BUY with a TP of Rs 20,000/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
detail (1-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Axis Direct
External broker reports(aggregated public sources)
Axis Direct
IndiaEquity Bottom-Up

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. Content available... 

Zoom:
NaN%
x